Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Galecto Biotech AB

www.galecto.com

Latest From Galecto Biotech AB

Seventure Reaffirms Microbiome Confidence With New €200m Fund

With its first microbiome fund completing its investment period, French venture capitalist Seventure Partners has raised more than €100m of a €200m target for its second microbiome-focused fund.

Financing StartUps and SMEs

Finance Watch: VC Deals Keep Up Fast Pace With $1.1bn In Less Than Three Weeks

Finance Watch has noted $1.1bn worth of venture capital deals so far in 2019. Meanwhile, public offerings continue to be muted by the US government shutdown, though Revance and others sold shares. Also, Five Prime and others reveal layoffs and strategic shifts.

Financing StartUps and SMEs

Galecto Funnels Funding Into Phase II For Inhaled IPF Therapy

Galecto Biotech recently raised €79m in a Series C funding round. Chief medical officer Richard Marshall spoke to Scrip about how it plans to invest the capital in its pipeline treatment for idiopathic pulmonary fibrosis.

Financing Respiratory

Venture Funding Deals: Gotham Raises $54m To Advance Epitranscriptomics

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced September and October 2018.
Deals Financing
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Pulmonary
  • Therapeutic Areas
  • Cancer
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Denmark
  • Parent & Subsidiaries
  • Galecto Biotech AB
  • Senior Management
  • Hans T Schambye, MD, PhD, CEO
    Richard Marshall, MD, PhD, CMO
    Anders Pedersen, COO
  • Contact Info
  • Galecto Biotech AB
    Phone: 70 70 52 10
    Cobis Science Park, Ole Maaloes Vej 3
    Copenhagen , DK-2200
    Denmark
Advertisement
Advertisement
UsernamePublicRestriction

Register